Dr. Stefan James and Dr. C Michael Gibson Discuss: SWEDEGRAFT – No-touch vein grafts in coronary artery bypass grafting August 31, 2024 Disclosures: TBD
Dr. Jung-Min Ahn and Dr. C Michael Gibson Discuss: ASSURE DES – Perioperative antiplatelet therapy in patients with coronary stents before non-cardiac surgery August 31, 2024 Disclosures: TBD
Dr. Erwan Donal and Dr. C Michael Gibson Discuss: Tri.fr trial – Multicentric randomised evaluation of the transcatheter edge-to-edge repair in the treatment of severe isolated secondary tricuspid regurgitation August 31, 2024 Disclosures: TBD
Dr. Volker Rudolph, Dr. Stephan Baldus and Dr. C Michael Gibson Discuss: MATTERHORN – Transcatheter versus surgical mitral valve repair in patients with heart failure and secondary mitral regurgitation August 31, 2024 Disclosures: TBD
Dr. Stefan Anker and Dr. C Michael Gibson Discuss: RESHAPE-HF2 – Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure August 31, 2024 Disclosures: TBD
Dr. Paul Ridker and Dr. C Michael Gibson Discuss: Thirty-year cardiovascular outcomes in women based on C-reactive protein, LDL cholesterol, and lipoprotein(a) August 31, 2024 Disclosures: TBD
Dr. Johanne Silvain, Dr. Gilles Montalescot and Dr. C Michael Gibson Discuss: ABYSS – Beta blocker interruption in post-myocardial infarction patients August 30, 2024 Disclosures: TBD
Dr. Mikhail Kosiborod and Dr. C Michael Gibson Discuss: Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials August 30, 2024 Disclosures: TBD
Dr. Leslie Cho and Dr. C. Michael Gibson Review: Multiple analyses from the Clear Outcomes Study presented at ACC 2024 including those regarding Gender, Hispanic and Obesity s/b Esperion April 19, 2024 Disclosures: TBD
Dr. Moritz Seiffert and Dr. C. Michael Gibson Discuss: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement In Patients At Low To Intermediate Risk: One Year Outcomes Of The Randomized DEDICATE-DZHK6 Trial April 19, 2024 Disclosures: TBD
